CDK4 and colorectal carcinoma: In colorectal carcinomas (CRCs), the therapeutic potential of CDK4/6 inhibitors has been evaluated in combination with other drugs, such as immune checkpoint, Raf, and mitogen-activated protein kinase (MAPK) inhibitors [8].